Références
Puéchal X, Dernis E. Manifestations articulaires des affections intestinales. EMC — Appar Locomoteur 2006;1:1–7.
Pedersen SJ, Weber U, Ostergaard M. The diagnostic utility of MRI in spondyloarthritis. Best Pract Res Clin Rheumatol 2012;26:751–66.
Leclerc-Jacob S, Lux G, Rat AC, Laurent V, Blum A, Chary-Valckenaere I, et al. The prevalence of inflammatory sacroiliitis assessed on magnetic resonance imaging of inflammatory bowel disease: a retrospective study performed on 186 patients. Aliment Pharmacol Ther 2014;39:957–62.
De Keyser F, Baeten D, Van den Bosch F, De Vos M, Cuvelier C, Mielants H, et al. Gut inflammation and spondyloarthropathies. Curr Rheumatol Rep 2002;4:525–32.
Kahn MF, Bouchon JP, Chamot AM, Palazzo E. Chronic enterocolopathies and SAPHO syndrome. 8 cases. Rev Rhum Mal Ostéo-Articul 1992;59:91–4.
Orchard T, Wordsworth B, Jewell D. Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history. Gut 1998;42:387–91.
Bayless TM, Stevens MB. Letter: Granulomatous synovitis and Crohn’s disease. N Engl J Med 1976;294:903.
Bandinelli F, Milla M, Genise S, Giovannini L, Bagnoli S, Candelieri A, et al. Ultrasound discloses entheseal involvement in inactive and low active inflammatory bowel disease without clinical signs and symptoms of spondyloarthropathy. Rheumatology 2011;50:1275–9.
Lioté F, Frazier A, Quemeneur AS, Ea HK. Le pied et la cheville des spondyloarthrites. Rev Rhum Monographies 2014;81:115–9.
Amor B, Dougados M, Mijiyawa M. Criteria of the classification of spondylarthropathies. Rev Rhum Mal Ostéo-Articul 1990;57:85–9.
Sieper J, van der Heijde D, Landewé R, Brandt J, Burgos-Vagas R, Collantes-Estevez E, et al. New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis international Society (ASAS). Ann Rheum Dis 2009;68:784–8.
Sandborn WJ, Stenson WF, Brynskov J, Lorenz RG, Steidle GM, Robbins JL, et al. Safety of Celecoxib in Patients With Ulcerative Colitis in Remission: A Randomized, Placebo-Controlled, Pilot Study. Clin Gastroenterol Hepatol 2006;4:203–11.
El Miedany Y, Youssef S, Ahmed I, El Gaafary M. The Gastrointestinal Safety and Effect on Disease Activity of Etoricoxib, a Selective Cox-2 Inhibitor in Inflammatory Bowel Diseases. Am J Gastroenterol 2006;101:311–7.
Braun J, Baraliakos X, Listing J, Davis J, van der Heijde D, Haibel H, et al. Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents. Arthritis Rheum 2007;57:639–47.
Maksymowych WP, Jhangri GS, Fitzgerald AA, LeClercq S, Chiu P, Yan A, et al. A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug–refractory ankylosing spondylitis. Arthritis Rheum 2002;46:766–73.
Dubost J-J, Tournadre A, Soubrier M, Ristori J-M. Arthrite septique à pyogène de l’adulte. EMC — Appar Locomoteur 2010;5:1–17.
Dubost J-J, Tournadre A, Soubrier M, Ristori J-M. Spondylodiscite infectieuse non tuberculeuse. EMC — Appar Locomoteur 2006;1:1–11.
Van Tjeerd-Pieter Cooper C, Samuels Brusse L, Leufkens H, Javaid MK, Arden NK. Inflammatory bowel disease and the risk of fracture. Gastroenterology 2003;125:1591–7.
Melek J, Sakuraba A. Efficacy and Safety of Medical Therapy for Low Bone Mineral Density in Patients With Inflammatory Bowel Disease: A Meta-analysis and Systematic Review. Clin Gastroenterol Hepatol 2014;12:32–44.e5.
Hindorf U, Lindqvist M, Hildebrand H, Fagerberg U, Almer S. Adverse events leading to modification of therapy in a large cohort of patients with inflammatory bowel disease. Aliment Pharmacol Ther 2006;24:331–42.
Bannwarth B. Drug-induced musculoskeletal disorders. Drug Saf Int J Med Toxicol Drug Exp 2007;30:27–46.
De Bandt M, Sibilia J, Le Loet X, Prouzeau S, Fautrel B, Marcelli C, et al. Systemic lupus erythematosus induced by antitumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther 2005;7:R545–R551.
Costa MF, Said NR, Zimmermann B. Drug-Induced Lupus due to Anti-Tumor Necrosis Factor a Agents. Semin Arthritis Rheum 2008;37:381–7.
Moss AC, Brinks V, Carpenter JF. Review article: immunogenicity of anti-TNF biologics in IBD–the role of patient, product and prescriber factors. Aliment Pharmacol Ther 2013;38:1188–97.
Kneepkens EL, Wei JC, Nurmohamed MT, Yeo KJ, Chen CY, Horst-Bruinsma IE van der, et al. Immunogenicity, adalimumab levels and clinical response in ankylosing spondylitis patients during 24 weeks of follow-up. Ann Rheum Dis 2013; annrheumdis-2013-204185.
Hernigou P. Ostéonécroses non traumatiques des épiphyses de l’adulte. EMC — Appar Locomoteur 2006;1:1–15.
Belmatoug N, et al. L’actualité rhumatologique 1992;p. 338.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Frazier-Mironer, A., Gonzalez, F., Lioté, F. et al. Comment prendre en charge les douleurs ostéo-articulaires d’un patient souffrant de maladies inflammatoires chroniques intestinales ?. Acta Endosc 44, 292–296 (2014). https://doi.org/10.1007/s10190-014-0415-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10190-014-0415-8